Biologicals

Influenza

WHO biosafety risk assessment and guidelines for the production and quality control of human influenza vaccines containing the pandemic influenza A H1N1 (2009) virus: Update

H1N1 specific-update of TRS 941, Annex 5

Proposed Guidelines: Regulatory Preparedness for Human Pandemic Influenza Vaccines

WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines

Recommendations for the production and control of influenza vaccine (inactivated)

WHO Technical Report Series, No. 927, 2005, Annex 3

Influenza vaccine, live

Title: Requirements for Influenza Vaccine (Live); Adopted 1978, TRS No 638, Annex 3

UPCOMING EVENTS

WHO Drafting Group Meeting on the Revision of TRS 962, Annex 1

(Guidelines to assure the quality, safety and efficacy of recombinant human papillomavirus virus-like particle vaccines) 29-30 April 2014, WHO/HQ, Geneva

Implementation Workshop on Evaluation of Biotherapeutic Products and Evaluation of Similar Biotherapeutic products with emphasis on Monoclonal Antibody Products

13-16 May 2014, Seoul, The Republic of Korea

CONTACTS

Quality, Safety and Standards (QSS)
Immunization, Vaccines and Biologicals (IVB)
World Health Organization (WHO)
Avenue Appia 20
1211 Geneva 27, Switzerland
Fax No. +41 22 7914971